Clarity Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 5:11 AM
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
9.93
Dividend yield
-
Beta
1.24
Market cap
$1.04B
Enterprise value
$812.79M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 69 |
| Website | https://www.claritypharmaceuticals.com |
| Mailing address | National Innovation Centre 4 Cornwallis Street Eveleigh Sydney NSW 2015 Australia |
| Phone / Fax | 61 2 9209 4037 / 61 2 9209 4037 |
Dividends
More: Clarity Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Clarity Pharmaceuticals paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CU6 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Clarity Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Alan John Taylor Ph.D. | Executive Chairman | ||
| Ms. Michelle Parker | CEO, MD & Executive Director | ||
| Mr. David K. Green BEc., CA | Chief Financial Officer | ||
| Dr. Colin David Biggin Ph.D. | COO & Non-Independent Executive Director | ||
| Dr. Matthew Harris BSc., M.B.A., Ph.D. | Chief Scientific Officer | ||
| Ms. Lisa Sadetskaya | Director of Corporate Communications. | ||
| Ms. Mary Bennett | Head of People & Culture | ||
| Mr. Shaemus Gleason | Executive Vice President of Operations | ||
| Dr. Othon Gervasio | Chief Medical Officer | ||
| Ms. Eva Lengyelova | Executive Vice President of Clinical Development |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-823.18%
Return on assets
-33.76%
Return on equity
-54.37%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Clarity Pharmaceuticals is 1.04B and its enterprise value is 812.79M. The enterprise value to revenue ratio of CU6 is 85.89. The enterprise value to EBITDA ratio of CU6 is -11.79.
The CU6's stocks Beta value is 1.24 making it 24% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Clarity Pharmaceuticals (CU6)
Clarity Pharmaceuticals (ASX:CU6) Frequently Asked Questions
1. What is Clarity Pharmaceuticals's Stock Symbol?
Clarity Pharmaceuticals trades on ASX under the ticker symbol "CU6".
2. What is Clarity Pharmaceuticals's stock price today?
One share of CU6 stock can currently be purchased for approximately $2.79.
3. How can I contact Clarity Pharmaceuticals?
Clarity Pharmaceuticals's mailing address is National Innovation Centre 4 Cornwallis Street Eveleigh Sydney NSW 2015 Australia. The company can be reached via phone at 61 2 9209 4037.
4. What is Clarity Pharmaceuticals's official website?
The official website of Clarity Pharmaceuticals is https://www.claritypharmaceuticals.com.